Provider review
Found Review: It Attributes the 15–20% to the Brands, Not to Its Own Compounds
Found is the only insurance-first operator among the companies we track: signup opens with a coverage check rather than a price, and it sells the branded GLP-1s alongside compounded ones. That structure produces the finding, and it is to Found’s credit — its headline claim, "Up to 15-20% weight loss with Wegovy® and Zepbound®", attaches those figures by name to the two approved products they came from.
Found is structured differently from everything else we track, and the difference works in a buyer's favor more often than not. It leads with an insurance check rather than a price, it sells the actual approved drugs alongside compounded copies, and when it quotes the famous weight-loss figures it credits them to Wegovy and Zepbound by name instead of implying its own compounded preparation produced them. It even explains that some of what it prescribes is approved for a different condition entirely. Those are the marks of a company that expects to be read carefully. What it will not tell you is where it operates: there is no state list at all, only a note that prescriptions are "not available in all states", and for the compounded line no pharmacy, no category and no test result. Budget on $289 a month rather than $169, and on medication being billed separately from the membership.
Worth trusting if
- You have a PPO plan, because Found is in-network with PPO plans only and says covered members save about seventy-five dollars a month on the fee.
- You want the drug the trial actually tested, because Found prescribes Wegovy, Zepbound, Ozempic and Mounjaro beside its compounded line.
- You will commit to a twelve-month plan, because that is where the advertised cash figure and the figure you pay finally meet.
Be skeptical if
- You budget by the calendar month, because the monthly plan renews every four weeks — thirteen charges a year, not twelve.
- You are counting on the price you read on the pricing page, because the plan the walk was matched to is a Med Kit and its rates are published nowhere.
- You may change your mind, because the fee is refundable only within three days and the medication never is.
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens joinfound.com. A link is not a recommendation to take anything.
Provenance
What Found actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded Semaglutide — $169 a month advertised; the verified figure you actually pay is $289, billed monthly. Medication cost is separate from the membership — Found's own note reads that insurance covers "1 in 3 Americans with copays under $30/visit for most", with "Medication cost sep[arate]".
- Compounded Tirzepatide — Priced within the same membership structure as its semaglutide; $169 advertised against a verified $289 a month, with medication cost separate from the membership fee.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to Found.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Found’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded SemaglutideSemaglutide · Compounded (503A)Claim matches the trials
“Up to 15-20% weight loss with Wegovy® and Zepbound®. […] Proven weight loss, the affordable way. Start with a free insurance check. Affordable GLP-1s, delivered fast. Covered by top insurance plans. […] Certain GLP-1 medications are only FDA approved to treat conditions other than weight but may be prescribed to help aid in weight loss. Rx are up to a medical provider's discretion and not available in all states.”
Read on the Found site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg — the Wegovy program, roughly 14.9% weight loss from baseline over 68 weeks. No compounded semaglutide has been through a registered trial.
The attribution is the point, and Found gets it right where most of this category gets it wrong. "Up to 15-20% weight loss WITH WEGOVY® AND ZEPBOUND®" credits the figures to the two approved products that produced them, by brand name, rather than presenting them as what Found's compounded preparation will do for you. "Up to" correctly marks them as ceilings. And the disclaimer beneath is genuinely informative rather than boilerplate: "Certain GLP-1 medications are only FDA approved to treat conditions other than weight but may be prescribed to help aid in weight loss" — an accurate description of off-label prescribing for Ozempic and Mounjaro, which Found also sells. What is left unstated is the standing caveat: the compounded semaglutide Found dispenses is not the product those figures came from, and no compounded semaglutide has been through a registered trial.1
Compounded TirzepatideTirzepatide · Compounded (503A)Claim matches the trials
“Up to 15-20% weight loss with Wegovy® and Zepbound®. […] Our expert providers can help find the right medication for you. […] Rx are up to a medical provider's discretion and not available in all states.”
Read on the Found site, August 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tirzepatide — the Zepbound program, roughly 20% mean reduction at the highest tolerated dose over 72 weeks.
The 20% end of Found's range belongs to Zepbound and is credited to it by name. Found makes no molecule-specific efficacy claim beyond that, and no claim at all that its compounded tirzepatide reproduces the branded result. Because it also sells Zepbound and Mounjaro directly, a patient reading the figure has a genuine route to the product it describes — which is not true of sellers that quote the same numbers while offering only a compounded copy.2
Dispensing chain
Who actually fills your prescription
Read the full account
No dispensing pharmacy is named. Found's structure makes that less consequential than it is elsewhere in this market, though it does not remove the gap: because it sells the BRANDED products — Ozempic, Mounjaro, Zepbound, Wegovy and Foundayo — alongside compounded semaglutide and tirzepatide, a patient who wants a manufactured product with a National Drug Code behind it can have one, and for those the manufacturer is known by definition. For the compounded line the same question as everywhere applies and is unanswered: which pharmacy, licensed where, under which category. Neither 503A nor 503B is stated anywhere. Found also prescribes metformin, which is an approved generic and not a compounded preparation at all — its catalog is unusually mixed for this category, and the site does not draw a clear line for a reader between the approved products, the generic and the compounded ones.
Read on the Found site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number, potency result, sterility result, named laboratory or batch lookup is published for any compounded product, and no pharmacy is named to ask. One structural fact softens this: for a substantial part of Found's catalog the question does not arise, because it dispenses APPROVED products — Ozempic, Mounjaro, Zepbound, Wegovy and Foundayo — which are manufactured under FDA-approved applications and carry National Drug Codes. A patient who wants a product whose identity and potency are assured by an approval rather than by a compounder's word can buy one here, which is not true at most companies in this market. For the compounded line, nothing is published, and Found states no compounding category. It cites no study, trial identifier or publication anywhere, though its efficacy figures are correctly attributed to the branded products by name.
Read on the Found site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
Not published — no state list appears anywhere; Found warns only that prescriptions are "not available in all states"
Read the full licensing claim
Found publishes no coverage list. Its own disclaimer states that "Rx are up to a medical provider's discretion and not available in all states", which tells you that exclusions exist without identifying any of them. None are named here because naming them would mean inventing them — not because none exist, and the site says plainly that some do. One claim you may see elsewhere — that Found is unavailable in California — has no support we could find: it traces to a page aimed at health insurers, and to a "No plans available for this state" message that belongs to an insurance-plan lookup, which lists insurance plans for a state rather than saying whether Found will treat you there. The 41-state figure that circulates for Found is the list of states where it accepts insurance, which is a different question from where it will prescribe.
Read on the Found site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with Found
We went through Found’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Open the three-minute eligibility quiz. It asks for your date of birth and state before anything else.
- Give your gender, sex at birth, height, weight and goal weight.
- Enter your full name. The screen says a third-party service may receive it and hand your health insurance details back to Found.
- Answer the medical screening, then leave an email address to save your progress. A phone number is asked for and can be skipped.
- About thirty screens in, choose how you want to take the medication. This is the first price on the walk, and it is quoted as a daily rate.
- Answer a further dozen lifestyle questions about sleep, fatigue, diet and digestion.
- Read the plan you have been matched to, then either run the insurance check or decline it to see cash prices.
- The four plan prices appear on the last screen before checkout.
- $149 a month is the pay-as-you-go cash price for the Med Kit plan the walk was matched to. It falls to $139 on three months, $129 on six and $99 on twelve, with medication included in every one.
- The monthly plan does not bill monthly. Found's own billing note on that screen says you are charged every four weeks on a 28-day cycle, which is thirteen charges in a year rather than twelve.
- The twelve-month plan renews every 48 weeks by the same note, so the year it names is four weeks short of a calendar year.
- None of those four figures appears on the public pricing page, which prices the GLP-1 program instead. The offer terms also exclude Med Kit plans from every advertised discount.
- The intake quotes price as a daily rate first: from four dollars a day for weekly injections, seven to twelve dollars a day for daily pills.
- The expected result shrinks as you go. The homepage credits up to 15-20% to Wegovy and Zepbound, the pricing page says up to 20% on average against a footnote reporting 12%, and the page you actually reach says an average of 10% in a year.
- Membership fees are refundable only within three days of purchase and before your first consultation. Medications, lab kits, copays and renewals are non-refundable once processed.
Found support
Assessment
What holds up, and what does not
- It attributes its efficacy figures to the products that earned them: "Up to 15-20% weight loss with Wegovy® and Zepbound®", by brand name, rather than draping them over a compounded preparation.
- It sells the approved products — Ozempic, Mounjaro, Zepbound, Wegovy and Foundayo — so a patient can buy a manufactured drug with an NDC rather than only a compounded copy.
- It states that "certain GLP-1 medications are only FDA approved to treat conditions other than weight but may be prescribed to help aid in weight loss" — an accurate account of off-label prescribing that most sellers omit.
Show 5 more
- It warns that prescriptions are "not available in all states" rather than claiming blanket nationwide coverage.
- "Up to" is used correctly, marking 15–20% as a ceiling rather than an expectation.
- Signup opens with a free insurance check rather than a price, which for an insured patient is the cheaper route and is not in Found's interest to lead with.
- It also prescribes metformin, an approved generic, so the catalog is not restricted to the highest-margin option.
- No FDA warning letter for Found.
- No state list is published anywhere, only a warning that prescriptions are "not available in all states" — so a prospective patient cannot tell before starting whether they qualify.
- No dispensing pharmacy is named for the compounded line, and no compounding category — 503A or 503B — is stated.
- No certificate of analysis, lot number, potency or sterility result is published for any compounded product.
Show 6 more
- $169 is advertised, but the verified monthly figure is $289.
- Medication cost is separate from the membership, so the headline figure is not the whole bill.
- The insurance framing does most of the persuading — "covered by insurance for 1 in 3 Americans" means it is not covered for two in three.
- The catalog mixes approved products, an approved generic and compounded preparations without drawing a clear line for a reader between them.
- No study, trial identifier or publication is cited anywhere, even though the figures quoted come from two well-known trials.
- It sells no peptide beyond the GLP-1s.
Verdict
The bottom line
This is the correct way to cite a trial result, and it is worth knowing what it costs to get it: the numbers belong to Wegovy and Zepbound, so if you end up on the compounded line they are not your numbers. Run the insurance check first — it is free, it is the first thing Found asks, and it is the only route here where the drug you take is the drug the trial tested.
Opens joinfound.com. A link is not a recommendation to take anything.
The figures belong to the brands, and Found says so
Almost every company in this review series quotes a weight-loss percentage. The question that separates them is whose result it was.
Found's headline:
"Up to 15-20% weight loss with Wegovy® and Zepbound®*"
Those figures are real — roughly 15% for semaglutide 2.4 mg in the STEP program and around 20% for tirzepatide at its highest tolerated dose in SURMOUNT-1 1 2 — and Found attaches them to the two approved products by brand name. It does not say "our semaglutide produces 15% weight loss". It says Wegovy and Zepbound do, which is what the trials showed.
That distinction is the entire subject of two open FDA warning letters against other companies in this same review wave. Found makes the correct attribution unprompted.
It goes further, with a disclaimer that actually informs:
"Certain GLP-1 medications are only FDA approved to treat conditions other than weight but may be prescribed to help aid in weight loss. Rx are up to a medical provider's discretion and not available in all states."
That is an accurate description of off-label prescribing — Ozempic and Mounjaro are approved for type 2 diabetes, and Found sells both. Most sellers in this category leave a reader to assume the approval covers the use.
What Found does not add is the standing caveat: the compounded semaglutide and tirzepatide it also sells are not the products those figures came from, and no compounded GLP-1 from any seller has been through a registered trial.
Full analysis — 4 more sectionsA different shape of business · The claim this review will not make about Found · What you will pay · What this means if you are buying
A different shape of business
Found is the only insurance-first operator here. Signup opens with a free insurance check rather than a price, and its catalog is unusually mixed:
- Approved brands — Ozempic®, Mounjaro®, Zepbound®, Wegovy®, Foundayo™
- Compounded semaglutide and tirzepatide
- Metformin, an approved generic
- A microdosing program
That matters for a reason this site cares about. A patient who wants a medicine whose identity and potency are guaranteed by an FDA approval and a National Drug Code — rather than by a compounder's word — can buy one here. At most companies in this market the compounded copy is the only thing on offer.
It also means the usual quality question is narrower rather than absent. For the compounded line, Found names no pharmacy, states no compounding category, and publishes no certificate of analysis, lot number or test result. The site does not clearly separate, for a reader, which products in its catalog are approved and which are compounded.
The claim this review will not make about Found
There is one thing this review deliberately does not say, and the reason is worth a minute of your time.
You may read elsewhere that Found is unavailable in California. We found no evidence for that claim, and we won't repeat it.
It comes from misreading one page two different ways. The page at joinfound.com/health-plans is a B2B page selling Found's program to health insurers — it contains nothing about patient state availability. And a "No plans available for this state" message that appears during signup sits beneath an insurance-plan lookup: it describes which insurance plans are listed for a state, not whether Found will treat a patient living there.
Neither substantiates a service exclusion. That would be a negative claim about a real company, with no evidence behind it.
What can be said is what Found says: prescriptions are "not available in all states". Exclusions exist. Found does not name them, and no state list is published anywhere on the site. *(A 41-state figure circulates for Found; that is the list of states where it accepts insurance, which is a different question from where it will prescribe.)*
What you will pay
$169 a month is the advertised figure. Work through signup and the verified figure is $289 a month.
And the membership is not the whole bill. Found's own note reads that insurance covers "1 in 3 Americans with copays under $30/visit for most" — with medication cost separate. So the number to plan around is a membership fee plus a medication cost, against a one-in-three chance of insurance meaningfully reducing it.
The insurance framing is doing a lot of the persuading. "Covered by insurance for 1 in 3 Americans" is the same sentence as "not covered for two in three".
What this means if you are buying
If you have insurance, start here — the free check costs nothing and Found leading with it rather than with a price is not in its own interest.
If you want a branded GLP-1, Found is one of the few places in this market that will actually sell you one, and for those products the questions this site usually asks about pharmacy identity and lot testing are answered by the approval itself.
If you want the compounded version, you are in the same position as everywhere else: no pharmacy named, no category stated, no certificate published — with the difference that Found has not pretended the branded trial figures belong to it.
Budget $289 a month plus medication, not $169. And do not assume you are eligible until the intake tells you, because Found publishes no state list.
Questions
Frequently asked questions
Are Found's weight-loss figures about its own products?
No, and Found says so — which is the best thing about the claim. Its headline reads "Up to 15-20% weight loss with Wegovy® and Zepbound®", crediting the figures to the two approved products that produced them rather than to the compounded semaglutide and tirzepatide it also sells. The numbers match the trials, and "up to" correctly marks them as ceilings rather than typical outcomes. Blurring exactly this distinction is what two other companies in this review wave are under open FDA warning letters for. Found also adds an unusually informative disclaimer: "certain GLP-1 medications are only FDA approved to treat conditions other than weight but may be prescribed to help aid in weight loss" — an accurate description of off-label prescribing for Ozempic and Mounjaro, both of which it sells.
Does Found serve my state?
It does not publish a list, so the intake is the only way to find out. Found's own disclaimer says prescriptions are "not available in all states", which confirms that exclusions exist without naming any. One claim you may see elsewhere — that Found is unavailable in California — has no support we could find: it traces to a page aimed at health insurers, and to a "No plans available for this state" message that belongs to an insurance-plan lookup rather than to a service gate. A 41-state figure also circulates for Found; that is where it accepts insurance, which is a different question from where it will prescribe.
What does Found cost?
$169 a month is advertised; work through signup and the verified figure is $289 a month. Two things to plan around beyond that. Medication cost is separate from the membership, so the headline is not the whole bill — Found's own note pairs "copays under $30/visit for most" with medication billed separately. And the insurance framing carries a figure worth reading both ways: "covered by insurance for 1 in 3 Americans" also means not covered for two in three. If you are insured, the free insurance check that opens signup is genuinely the right first step and costs nothing.
Can I get a branded GLP-1 from Found?
Yes, and it is one of the few companies in this market where that is true. Found sells Ozempic®, Mounjaro®, Zepbound®, Wegovy® and Foundayo™ alongside compounded semaglutide and tirzepatide, plus metformin as an approved generic. For the branded products the questions this site normally asks — which pharmacy compounded it, was the lot tested, what was actually in the vial — are answered by the FDA approval and the National Drug Code behind the product. For the compounded line, Found names no pharmacy, states no compounding category, and publishes no certificate of analysis or test result, exactly like the rest of this category. The site does not clearly signpost for a reader which products in its catalog are which.
Glossary
Key terms
Show definitions
- Off-label prescribing
- Prescribing an approved drug for a use its approval does not cover. It is lawful and routine. Ozempic and Mounjaro are approved for type 2 diabetes and are widely prescribed for weight — a distinction Found states explicitly and most sellers omit.
- National Drug Code
- The identifier carried by an FDA-approved manufactured drug product. Compounded preparations have none, which is why the questions about pharmacy identity and lot testing only arise for them.
Compare
Others selling what Found sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Found's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.